Rep. Robert Bresnahan, Jr. Buys STERIS plc (NYSE:STE) Shares

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of STERIS plc NYSE: STE. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in STERIS stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
• Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
• Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.

STERIS Stock Performance

STERIS stock traded up $0.85 during trading hours on Wednesday, hitting $226.57. 152,823 shares of the stock traded hands, compared to its average volume of 528,271. STERIS plc has a 1 year low of $197.82 and a 1 year high of $248.24. The stock has a market capitalization of $22.26 billion, a price-to-earnings ratio of 48.10 and a beta of 0.92. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. The firm's 50 day moving average price is $223.03 and its 200-day moving average price is $220.88.

Remove Ads

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. As a group, equities analysts expect that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 21st. Investors of record on Thursday, February 20th were paid a $0.57 dividend. The ex-dividend date was Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a yield of 1.01%. STERIS's dividend payout ratio (DPR) is 48.41%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Avalon Trust Co acquired a new stake in shares of STERIS in the fourth quarter valued at about $30,000. Human Investing LLC purchased a new position in STERIS during the fourth quarter worth about $31,000. Anfield Capital Management LLC raised its stake in shares of STERIS by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 91 shares during the period. Central Pacific Bank Trust Division increased its holdings in STERIS by 65.5% in the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 76 shares during the last quarter. Finally, Manchester Capital Management LLC increased its holdings in STERIS by 182.7% in the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 137 shares during the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on STE. JMP Securities reiterated a "market outperform" rating and set a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. Stephens reiterated an "overweight" rating and issued a $240.00 target price on shares of STERIS in a research note on Thursday, February 6th. Finally, Piper Sandler lifted their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, STERIS has a consensus rating of "Moderate Buy" and a consensus price target of $258.75.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.